Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

Abstract: Co-expression of T1R2 and T1R3 results in a taste receptor that responds to sweet taste stimuli, including naturally occurring and artificial sweeteners. Cells such as U2-OS, which express a functional sweet receptor, can be used in cell-based assays to detect cellular responses to tastants.

Abstract: The invention provides processes for preparing purified cell-binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell-binding agent cytotoxic agent conjugate and one or more impurities to a polyvinyl difluoride (PVDF) membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell-binding agent cytotoxic agent conjugate.

Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.

Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

Abstract: It has been found that a main effect (immunosuppressive activity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i2 or G?i3, and that an adverse effect (cardiotoxicity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i1.

Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.

Abstract: The present invention relates to antibodies binding specifically to CCR9, and to antigen-binding fragments thereof. It also relates to uses thereof and diagnostic methods using said antibodies.

Abstract: Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent.

Abstract: Methods, systems and devices are implemented in connection with light-responsive ion channel molecules. One such method is implemented using a light-activated ion channel molecule that responds to a light stimulus. The method includes engineering the light-activated ion channel molecule in a cell; and activating the ion channel molecule, in response to light stimulus that is provided to the ion channel molecule and that has properties that do not activate a ChR2 ion channel, to allow ions to pass through the light-activated ion channel molecule.

Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.

Abstract: The invention encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.

Abstract: The present invention concerns the field of ion channels, and in particular relates to peptides which are suitable for use in the treatment of conditions where the L-type calcium channel (LTCC) density and function is altered. LTCCs are located on the membrane of all excitable cells and control the small voltage gradient across the plasma membrane by allowing the flow of Ca2+ ions down their electrochemical gradient. This Ca2+ flux is critical for numerous processes including cardiac action potential propagation, muscle contraction, Ca2+-dependent gene expression, synaptic efficacy, and cell survival by contributing to various signaling cascades. Reduction of the inward calcium current (ICa) conducted through the LTCCs is seen in several diseases and medications to improve or restores impaired intracellular Ca2+ homeostasis are limited. The present invention reports mimetic peptides (MPs) that through a novel mechanism directly targets LTCCs and, by modulation of LTCC density and function, increases ICa.

Abstract: This invention relates to the administration of an animal immunoglobulin source to mammals such as dairy cattle to improve milk production without negatively affecting reproductive parameters.

Abstract: Chemerin is a chemoattractant that selectively directs intra-tumor recruitment of CMKLR1+ cells. Blockade of CCRL2 from binding to chemerin in non-neoplastic tumor cells, e.g. peri-tumor stromal and/or hematopoietic cells allows for redistribution of chemerin into the tumor and enhanced responsiveness against a tumor.

Abstract: Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates.

Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.